Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $60.4 million.

  • Stoke Therapeutics' Shares Outstanding (Diluted Average) rose 720.01% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 720.01%. This contributed to the annual value of $54.0 million for FY2024, which is 2276.18% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Shares Outstanding (Diluted Average) is $60.4 million, which was up 720.01% from $59.7 million recorded in Q2 2025.
  • Stoke Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $60.4 million during Q3 2025, with a 5-year trough of $37.4 million in Q1 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $48.1 million, with a median of $44.3 million in 2023.
  • Data for Stoke Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY increase of 2843.8% (in 2025) and a maximum YoY decrease of 702.14% (in 2025) over the last 5 years.
  • Quarter analysis of 4 years shows Stoke Therapeutics' Shares Outstanding (Diluted Average) stood at $38.9 million in 2022, then grew by 13.1% to $44.0 million in 2023, then rose by 22.76% to $54.0 million in 2024, then grew by 11.83% to $60.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $60.4 million in Q3 2025, compared to $59.7 million in Q2 2025 and $59.4 million in Q1 2025.